

# CELL BIOTECH

---

Probiotics & Microbiome company



## 2026 1Q Earnings Release

2026. 05.

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to differ from those stated or implied in this material.

# Q1 Earnings Summary

Revenue up 30% to KRW 14.6 billion, operating profit up 134% to KRW 3.2 billion

Domestic revenue up 14.8%, overseas revenue up 43.8%

Duolac brand sales up 20% to KRW 7.7 billion, OEM/ODM sales up 60% to KRW 7.3 billion, Raw material sales down -33% to KRW 0.9 billion

(unit : KRW 100 mil)


	2025 1q	% of revenue	2026 1q	% of revenue	YoY(%)
Revenue	112.3		145.97		30.0
Domestic	53.4	47.5	61.27	42.0	14.8
Overseas	58.9	52.5	84.7	58.0	43.8
	2025 1q	Profit margin (%)	2026 1q	Profit margin (%)	YoY(%)
Operating profit	13.6	12.1	31.9	21.8	134.3
Net Profit	20.7	18.4	53.5	36.7	158.5

# Revenue trends

Q1 revenue KRW 14.6 billion, yoy +30%, qoq -0.2%


## Quarterly revenue

(unit : KRW mil)



## Full year revenue

(unit : KRW mil)




# Profit trends

Q1 operating profit KRW 3.2 billion, yoy + 134%  
 Net Profit KRW + 5.3 billion, yoy + 158%


## Quarterly profit

(unit : KRW mil)




## Full year profit

(unit : KRW mil)



# Revenue breakdown

Q1 revenue of Duolac brand + 20% to 7.7 KRW bil., OEM/ODM + 73% to 6.0 KRW bil., and raw material -0.2% to 0.9 KRW bil.



## Microbiome R&D

- 1) Microbiome First-in-Class anticancer pipeline 'PP-P8' clinical phase 1 IND submitted (Mar 5, 2021)
- 2) Acquisition European patent of PP-P8 (Apr 1, 2021) (patent number EP3453718)
- 3) Acquired US patent for Probiotics drug delivery system (22. 12. 20)
- 4) P8 anticancer mechanism paper MOA (23.06.07)  
Anti-Cancer Roles of Probiotic-Derived P8 Protein in Colorectal Cancer Cell Line DLD-1, Int. J. Mol. Sci, 2023
- 5) Cellbiotech, Colorectal Cancer Drug Phase 1 Clinical Trial Plan Approved by Korea MFDS (Mar 20, 2024)
- 6) Cellbiotech starts phase 1 of microbiome colorectal cancer drug 'PP-P8'

<https://www.hankyung.com/article/202502194939i>

No. 1 in global export for 12 consecutive years

- 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world for 12 consecutive years



<https://www.mk.co.kr/en/it/11341049>

## FDA GRAS World's Most Listed

1) Cellbiotech "11 types of lactic acid bacteria secured FDA GRAS certification... The World's Largest Holdings"



<https://www.hankyung.com/article/202402222016i>

2) Cellbiotech, Probiotics Leading... Global Leap



<https://www.dailypharm.com/Users/News/NewsView.html?ID=309331&REFERER=NP>

“Now is the Era of K-Probiotics”

– Cellbiotech’s ‘Duolac’ Achieves No. 1 Market Share in Denmark, the Home Country

1) Surpassing Local Brand ‘Lactocare’ --- Assuming the Top Spot with a 46.6% Market Share



<https://n.news.naver.com/mnews/article/016/0002614577?sid=101>

# Consolidated Financial Summary

CELL BIOTECH

## Income statement

(unit : KRW 100 mil., %)

	2025 1q		2026 1q	
	Amount	Ratio	Amount	Ratio
Revenue	112.3	100.0	146.0	100.0
Gross profit	79.8	71.1	106.6	73.1
SG&A expenses	66.2	59.0	74.8	51.2
Operating profit	13.6	12.1	31.9	21.8
Consolidated net income	20.7	18.4	53.5	36.7

## Statement of financial position

(unit : KRW 100 mil., %)

	2025 .12	2026 1q
Assets	1,366	1,433
Current Assets	1037	1,070
Non current Assets	329	363
Liabilities	49	103
Current Liabilities	49	102
Non current Liabilities	1	1
Shareholder's Equity	1,316	1,330